Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
VSIG10L2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
VSIG10L2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of VSIG10L2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
VSIG2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
VSIG2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of VSIG2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
UTS2R Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
UTS2R Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of UTS2R sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
VSIG1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
VSIG1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of VSIG1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TOMM5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TOMM5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TOMM5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
VDR Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
VDR Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of VDR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
VPREB1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
VPREB1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of VPREB1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TLR7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TLR7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TLR7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TMEM35A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TMEM35A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TMEM35A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TMEM97 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TMEM97 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TMEM97 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TLR8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TLR8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TLR8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TLR9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TLR9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TLR9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →